AIM ImmunoTech shares rise 34.61% intraday after positive DURIPANC trial shows 19.7-month median survival with Ampligen and Imfinzi for metastatic pancreatic cancer.

AIM ImmunoTech surged 34.61% intraday, driven by positive mid-term results from its Phase 2 DURIPANC trial. The study showed a median survival of 19.7 months (8.6 months longer than standard care) and improved quality of life for patients receiving Ampligen in combination with AstraZeneca’s Imfinzi for metastatic pancreatic cancer. The company specializes in developing Ampligen, an immunotherapy targeting unmet needs in oncology, particularly for pancreatic cancer.